Accelerated Approval pathway for our ST-920 gene therapy product candidate for the treatment of Fabry disease.

Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences

BRISBANE, Calif. --(BUSINESS WIRE)--Aug. 31, 2021-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will be participating in fireside chats at the following investor conferences: 2021 Virtual Wells Fargo Healthcare Conference Date: Friday,